OSR (NASDAQ:OSRH) Announces Earnings Results

OSR (NASDAQ:OSRH) posted its earnings results on Friday. The company reported ($0.02) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $0.32 million for the quarter. OSR had a negative net margin of 363.26% and a negative return on equity of 7.24%.

OSR Stock Performance

Shares of OSRH stock traded up $0.03 during mid-day trading on Friday, reaching $0.32. 2,708,478 shares of the company’s stock traded hands, compared to its average volume of 620,130. The firm has a market capitalization of $11.10 million, a PE ratio of -0.96 and a beta of 0.56. OSR has a 12 month low of $0.25 and a 12 month high of $1.24. The firm has a 50 day moving average price of $0.39 and a two-hundred day moving average price of $0.47.

Hedge Funds Weigh In On OSR

A hedge fund recently bought a new position in OSR stock. Susquehanna International Group LLP purchased a new stake in shares of OSR Holdings, Inc. (NASDAQ:OSRH) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 55.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on OSRH. Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of OSR from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, OSR presently has a consensus rating of “Sell”.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.